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eTATE-OF-THE-ART PAPERS343NHLBI Working Group on ED Management of AHFS. Frank Peacock, Eugene Braunwald, William Abraham, Nancy Albert, John Burnett, Rob Christenson,
ean Collins, Deborah Diercks, Greg Fonarow, Judd Hollander, Art Kellerman, Mihai Gheorghiade,
oug Kirk, Phil Levy, Alan Maisel, Barry M. Massie, Christopher O’Connor, Peter Pang, Monica Shah,
eorge Sopko, Lynne Stevenson, Alan Storrow, John Teerlink
his paper details the substance and recommendations arising from a meeting convened by
he National Heart, Lung, and Blood Institute (NHLBI) to assess the challenges and
pportunities of emergency department (ED) management of acute heart failure syndrome
AHFS). All participants agreed that there is a critical need for evidence-based management
f AHFS in the ED. Of 18 Class I recommendations for AHFS treatment, only 1 has Level
f Evidence: A data. The attendees highlighted 2 areas that need urgent attention: 1) early
isk stratification to distinguish between low- and high-risk patients; and 2) a better
nderstanding of the pathophysiology of cardiac and noncardiac (particularly renal) injuries.
heir recommendations include proposals regarding the design and conduct of ED-based
linical trials and suggestions for improved methods to detect and monitor AHFS.TATE-OF-THE-ART PAPERS352Potential Role of Biomarkers in Determining Donor Heart Suitabilityamsidhar B. Dronavalli, Nicholas R. Banner, Robert S. Bonser
etermining if potential donor hearts are suitable for transplantation is difficult and fraught
ith risk. Dronavalli and colleagues proffer that biomarkers may improve the identification of
earts suitable for transplant and of those hearts likely to fail in the recipient. The literature
egarding the discriminant value of cardiac troponins, cytokines, inflammatory markers,
atriuretic peptides, and intracellular proteins is reviewed. A large trial is currently underway
hat will help to clarify this issue, and it is suggested that a multimarker panel may be most
ffective.(continued on page A-20)
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mLINICAL RESEARCH362HF in the VA System: Improved Survival But More Frequent Rehospitalizationaul A. Heidenreich, Anju Sahay, John R. Kapoor, Michael X. Pham, Barry Massie
eidenreich and colleagues analyzed trends over time in heart failure (HF) hospitalization
ithin the Veteran’s Affairs (VA) health care system, including patient characteristics,
reatment, rehospitalization, and mortality. From 2002 to 2006, HF admission rates remained
onstant at about 5 per 1,000 veterans. Mortality at 30 days decreased from 7.1% to 5.0%,
hile rehospitalization for HF within 30 days increased from 5.6% to 6.1%. After adjustment
or patient characteristics, the odds ratio for 30-day mortality for 2006 compared with 2002
as 0.54, but was 1.21 for rehospitalization. These results show divergent trends for mortality
nd rehospitalization, with important implications for measuring the quality of care.ditorial Comment: Christopher M. O’Connor, Mona Fiuzat, p. 369LINICAL RESEARCH372Long-Term Benefits for a Telephone Intervention in Patients With HFaniel Ferrante, Sergio Varini, Alejandro Macchia, Saúl Soifer, Raul Badra, Daniel Nul, Hugo Grancelli,
erna´n Doval, on behalf of the GESICA Investigators
errante and colleagues studied the efficacy of a telephone intervention aimed at improving
ducation and compliance in patients with heart failure (HF). The rate of death or
ospitalization for HF was compared 1 and 3 years after the trial ended for patients who
ere randomized to the telephone intervention or standard care for 1 year. The rate of death
r hospitalization for HF was lower in the intervention group (relative risk [RR]: 0.81 at 1
ear and RR: 0.88 at 3 years). These sustained benefits may be explained by the impact of the
ducational intervention on patients’ behavior and habits.ditorial Comment: Marvin A. Konstam, Varda Konstam, p. 379LINICAL RESEARCH382Mechanical Unloading With LVAD Increases Microvascular Density and Fibrosistavros G. Drakos, Abdallah G. Kfoury, Elizabeth H. Hammond, Bruce B. Reid, Monica P. Revelo,
rad Y. Rasmusson, Kevin J. Whitehead, Mohamed E. Salama, Craig H. Selzman, Josef Stehlik,
tephen E. Clayson, Michael R. Bristow, Dale G. Renlund, Dean Y. Li
his study by Drakos and colleagues investigated the alterations in myocardial microvascula-
ure, fibrosis, and hypertrophy after mechanical unloading of the failing heart with a left
entricular assist device (LVAD). Hemodynamic data and left ventricular tissue were collected
rom patients at LVAD implant and explant and from normal donors. Advanced digital
icroscopy provided a comprehensive whole-field, endocardium-to-epicardium evaluation. At
VAD explant, there was a 33% increase in microvascular density and a 36% decrease in
icrovascular lumen area. There was also a significant increase in interstitial and total
ollagen content. These new insights into the effects of LVAD unloading on microvasculature
ay guide future studies in reverse remodeling.(continued on page A-22)
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nLINICAL RESEARCH392Correlations Between Ventricular Remodeling and Mortality for Heart Failure Interventionsaniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam,
ames E. Udelson
hether therapy-induced changes in left ventricular ejection fraction (LVEF), end-diastolic
olume (EDV), and end-systolic volume (ESV) are predictors of mortality in patients with
eft ventricular dysfunction (LVD) is not established. Kramer and colleagues identified
andomized controlled trials (RCTs) of drug or device therapies that were powered for
ortality (“mortality” trials) and then looked for RCTs involving the same therapies that
escribed changes in LVEF and/or volumes over time (“remodeling” trials). The odds ratio
or death in the mortality trials was correlated with drug/device effects on LVEF
r  0.51), EDV (r  0.44), and ESV (r  0.48). In patients with LVD, short-term trial-
evel therapeutic effects of a drug or device on left ventricular remodeling are associated with
onger-term trial-level effects on mortality.ACUTE MYOCARDIAL INFARCTION CUTE MYOCARDIAL INFARCTION407Short DBT Is Most Critical in Patients With Early Arrival After Symptom Onsetruce R. Brodie, Bernard J. Gersh, Thomas Stuckey, Bernhard Witzenbichler, Giulio Guagliumi,
an Z. Peruga, Dariusz Dudek, Cindy L. Grines, David Cox, Helen Parise, Abhiram Prasad,
lexandra J. Lansky, Roxana Mehran, Gregg W. Stone
rodie and colleagues used data from 2 large trials to investigate the impact of door-to-
alloon time (DBT) on mortality for patients with ST-segment elevation myocardial
nfarction treated with primary percutaneous coronary intervention (PCI). Overall, 1-year
ortality was lower in patients with short versus long DBT (90 min vs. 90 min, 3.1% vs.
.3%). Short DBTs were associated with lower mortality in patients with early presentation
90 min: 1.9% vs. 3.8%) but not with later presentation (90 min: 4.0% vs. 4.6%). Short
BTs improve outcomes in patients with early presentation but have less impact on mortality
n patients presenting later. These data may be helpful in designing triage strategies for
atients presenting to non-PCI hospitals.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH414Improved Collateral Development With Cotransfection of VEGF-A and PDGF-Bhristian Kupatt, Rabea Hinkel, Achim Pfosser, Chiraz El-Aouni, Alexander Wuchrer, Andrea Fritz,
ranziska Globisch, Michael Thormann, Jan Horstkotte, Corinna Lebherz, Eckart Thein, Andrea Banfi,
eter Boekstegers
upatt and colleagues investigated the ability of cardiotropic adeno-associated viral vector
rAAV) to induce prolonged expression of vascular endothelial growth factor (VEGF)-A and
latelet derived growth factor (PDGF)-B in a rabbit hindlimb ischemia model and a pig
odel of hibernating myocardium. In rabbits, rAAV.VEGF-A strongly induced angiogenesis,
ut not collateral growth or perfusion. With VEGF-A/PDGF-B cotransfection, collateral
rowth and perfusion improved. In the pig model, rAAV.VEGF-A/PDGF-B increased
egional myocardial blood flow reserve and improved the ejection fraction, whereas
AAV.VEGF-A alone did not. Cotransfection with rAAV.VEGF-A/PDGF-B promotes
eovascularization and improves myocardial function.
